Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis

Company Overview

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company dedicated to discovering and developing novel pharmaceutical products that address significant unmet medical needs. Leveraging its proprietary gene knockout platform, the company identifies targets essential to disease processes and develops small-molecule inhibitors to modulate those targets. Lexicon’s research model emphasizes rapid target validation in genetically engineered animal models, accelerating the transition from discovery to clinical development.

The company’s first approved product, XERMELO® (telotristat ethyl), is indicated for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy. Building on this success, Lexicon is advancing a diversified pipeline of investigational therapies focused on metabolic diseases, gastrointestinal disorders, and chronic pain. Key clinical-stage assets include investigational agents for type 1 diabetes-associated hypoglycemia, diabetic peripheral neuropathy, and other rare disease indications.

Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon operates research and development facilities in the United States and maintains collaborative partnerships in Europe and Asia. The company’s scientific team comprises experts in molecular biology, medicinal chemistry, translational pharmacology, and clinical medicine. Through strategic alliances with academic institutions and industry partners, Lexicon expands its global reach and accelerates the development of innovative therapies.

Leadership at Lexicon is focused on delivering value through disciplined pipeline management and efficient clinical execution. Chief Executive Officer Jack W. Klempner brings extensive experience in drug development and commercialization, having held senior roles at several biotechnology companies. The management team’s expertise in both early-stage research and late-stage clinical operations underscores Lexicon’s commitment to translating genetic insights into life-changing treatments for patients worldwide.

Key Stats

• Today's Range: $1.05 to $1.13
• 50-Day Range: $0.53 to $1.13
• 52-Week Range: $0.28 to $2.45
• Volume: 3.26 million shs
• Average Volume: 6.89 million shs
• Market Capitalization: $390.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.67
• Consensus Rating: Hold

Lexicon Pharmaceuticals Stock Analysis - MarketRank™

Lexicon Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 486th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Lexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lexicon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.66) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lexicon Pharmaceuticals is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lexicon Pharmaceuticals is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lexicon Pharmaceuticals has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.67% of the float of Lexicon Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Lexicon Pharmaceuticals has recently decreased by 11.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexicon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Lexicon Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.67% of the float of Lexicon Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Lexicon Pharmaceuticals has recently decreased by 11.58%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.97

News Sentiment

Lexicon Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lexicon Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 6 people have searched for LXRX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.90% of the stock of Lexicon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LXRX Stock Analysis - Frequently Asked Questions

How have LXRX shares performed this year?

Lexicon Pharmaceuticals' stock was trading at $0.7385 at the beginning of the year. Since then, LXRX shares have increased by 46.2% and is now trading at $1.08.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings data on Tuesday, May, 13th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. The biopharmaceutical company earned $1.26 million during the quarter, compared to analyst estimates of $1.26 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 103.16% and a negative net margin of 568.04%.
Read the conference call transcript.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LXRX
• Previous Symbol: NASDAQ:LEXG
• CIK: 1062822
• Web: www.lexpharma.com
• Phone: (281) 863-3000
• Fax: 281-863-8010
• Employees: 140
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Lexicon Pharmaceuticals: $3.67
• High Price Target: $6.00
• Low Price Target: $1.00
• Potential Upside/Downside: +239.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$200.40 million
• Net Margins: -568.04%
• Pretax Margin: -568.04%
• Return on Equity: -103.16%
• Return on Assets: -54.95%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 2.22
• Quick Ratio: 2.22

Sales & Book Value

• Annual Sales: $31.08 million
• Price / Sales: 12.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.40 per share
• Price / Book: 2.70

Miscellaneous

• Outstanding Shares: 361,490,000
• Free Float: 311,245,000
• Market Cap: $390.41 million
• Optionable: Optionable
• Beta: 1.13